Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept

Detalhes bibliográficos
Principais autores:	Kavanaugh, A, Ritchlin, C, Malaise, MG, Wordsworth, P, Birbara, C, Weinberg, M
Formato:	Conference item
Publicado em:	2005

Registros relacionados

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
por: Choy, E, et al.
Publicado em: (2007)

Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan
por: Pei-Han Kao, et al.
Publicado em: (2015-09-01)

Adalimumab in treatment of psoriatic arthritis
por: V. V. Badokin
Publicado em: (2008-08-01)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, P, et al.
Publicado em: (2017)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
por: Landewé, R, et al.
Publicado em: (2019)

Is there still a place for methotrexate in severe psoriatic arthritis?
por: Renaud Felten, et al.
Publicado em: (2022-04-01)

Methotrexate in psoriasis and psoriatic arthritis
por: Coates, L, et al.
Publicado em: (2020)

Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
por: N. V. Chichasova, et al.
Publicado em: (2021-06-01)

Methotrexate in a psoriatic arthritis patient
por: K. V. Aleksanyan, et al.
Publicado em: (2022-12-01)

THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
por: Elena Yurievna Loginova, et al.
Publicado em: (2010-06-01)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
por: Coates, L, et al.
Publicado em: (2017)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Hermine I Brunner, et al.
Publicado em: (2020-09-01)

Efficacy and safety of adalimumab in the treatment of Rheumatoid Arthritis (RA) in real-life clinical practice: 1-year-results of the react study
por: Burmester, G, et al.
Publicado em: (2006)

Use of methotrexate in the treatment of psoriasis and psoriatic arthritis
por: Tatiana Viktorovna Korotaeva, et al.
Publicado em: (2013-06-01)

Long-term survival of methotrexate in psoriatic arthritis
por: N. Battafarano, et al.
Publicado em: (2011-06-01)

Differences in oxylipin profile in psoriasis versus psoriatic arthritis
por: Roxana Coras, et al.
Publicado em: (2021-07-01)

Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis
por: A. V. Rudakova, et al.
Publicado em: (2021-07-01)

Analysis of methotrexate use practice in patients with rheumatoid arthritis and psoriatic arthritis
por: S. A. Doktorova, et al.
Publicado em: (2023-09-01)

Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis
por: Philip J Mease, et al.
Publicado em: (2024-02-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
por: V. V. Didenko, et al.
Publicado em: (2021-05-01)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: Salvatore D'Angelo, et al.
Publicado em: (2019-12-01)

Should methotrexate have any place in the treatment of psoriatic arthritis?
por: Ye, W, et al.
Publicado em: (2019)

The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis
por: V. A. Keltsev, et al.
Publicado em: (2016-01-01)

Psoriatic arthritis
por: FitzGerald, O, et al.
Publicado em: (2021)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
por: E. Yu. Loginova, et al.
Publicado em: (2021-06-01)

The influence of adalimumab treatment on the systemic gene expression in patients with psoriatic arthritis – preliminary report
por: Agata Krawczyk, et al.
Publicado em: (2021-03-01)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
por: M Rodgers, et al.
Publicado em: (2011-02-01)

Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study
por: Ulf Lindström, et al.
Publicado em: (2023-05-01)

Early treatment with addition of low dose prednisolone to methotrexate improves therapeutic outcome in severe psoriatic arthritis
por: Vikram K Mahajan, et al.
Publicado em: (2013-01-01)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani MG, et al.
Publicado em: (2008-09-01)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
por: Soriano, ER, et al.
Publicado em: (2023)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Dafna D. Gladman, et al.
Publicado em: (2022-02-01)

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study
por: Coates, LC, et al.
Publicado em: (2022)

Gastrointestinal disease and psoriatic arthritis.
por: Williamson, L, et al.
Publicado em: (2004)

A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy
por: N. S. Rudneva, et al.
Publicado em: (2021-12-01)

Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
por: M. Teoli, et al.
Publicado em: (2012-01-01)

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial
por: Kristian Reich, et al.
Publicado em: (2022-05-01)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter M, et al.
Publicado em: (2019-06-01)

The reverse of the coin: Methotrexate and liver fibrosis in a group of psoriatic arthritis patients
por: Andreea Lili Barbulescu, et al.
Publicado em: (2020-12-01)

CLINICAL ASSESSMENT IN PSORIATIC ARTHRITIS
por: M.G. Catanoso, et al.
Publicado em: (2011-09-01)